Abstract:Background: Products containing delta-8-THC became widely available in most of the USA following the 2018 Farm Bill and by late 2020 were core products of hemp processing companies, especially where delta-9-THC use remained illegal or required medical authorization. Research on experiences with delta-8-THC is scarce, some state governments have prohibited it because of this lack of knowledge. Objective: We conducted an exploratory study addressing a broad range of issues regarding delta-8-THC to inform policy discussions and provide directions for future systematic research. Methods: We developed an online survey for delta-8-THC consumers, including qualities of delta-8-THC experiences, comparisons with delta-9-THC, and open-ended feedback. The survey included quantitative and qualitative aspects to provide a rich description and content for future hypothesis testing. Invitations to participate were distributed by a manufacturer of delta-8-THC products via social media accounts, email contact list, and the Delta8 Reddit.com discussion board. Participants (N = 521) mostly identified as White/European American (90%) and male (57%). Pairwise t tests compared delta-8-THC effect rating items; one-sample t tests examined responses to delta-9-THC comparison items. Results: Most delta-8-THC users experienced a lot or a great deal of relaxation (71%); euphoria (68%) and pain relief (55%); a moderate amount or a lot of cognitive distortions such as difficulty concentrating (81%), difficulties with short-term memory (80%), and alerted sense of time (74%); and did not experience anxiety (74%) or paranoia (83%). Participants generally compared delta-8-THC favorably with both delta-9-THC and pharmaceutical drugs, with most participants reporting substitution for delta-9-THC (57%) and pharmaceutical drugs (59%). Participant concerns regarding delta-8-THC were generally focused on continued legal access. Conclusions: Delta-8-THC may provide much of the experiential benefits of delta-9-THC with lesser adverse effects. Future systematic research is needed to confirm participant reports, although these studies are hindered by the legal statuses of both delta-8-THC and delta-9-THC. Cross-sector collaborations among academics, government officials, and representatives from the cannabis industry may accelerate the generation of knowledge regarding delta-8-THC and other cannabinoids. A strength of this study is that it is the first large survey of delta-8 users, limitations include self-report data from a self-selected convenience sample.

THC-O-Acetate: Scarce Evidence for a Psychedelic Cannabinoid

Delta-8-THC: Delta-9-THC's nicer younger sibling?

The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption

Psychedelic risks and benefits: A cross-sectional survey study

The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects

What Predicts Beneficial Outcomes in Psychedelic Use? A Quantitative Content Analysis of Psychedelic Health Outcomes

The Acute Effects Of Cannabis With And Without Cannabidiol In Adults And Adolescents: A Randomised, Double‐Blind, Placebo‐Controlled, Crossover Experiment

Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists

Inhaled Dimethyltryptamine (DMT): Use Patterns and Predictors of Consumption Frequency

Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder

Do Psychedelic Trips Open the Door to Messages from God, Spirits, Transcendent Realities, or the Devil? Links with Attitudes About Psychedelics, Opinions About Legalization, and Interest in Personal Use

μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges

A Critical Overview of Recent Clinical Trials and Suggested Guidelines for Future Research

The psychedelic mind: Current user perceptions of psychedelic drugs and their use

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants

Neural effects of psychedelics: Complexity the key word

The potential of 5‐methoxy‐N,N‐dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action

Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties

An emerging trend in Novel Psychoactive Substances (NPSs): designer THC

Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey

Psychedelic research at a crossroads